Van ECK Associates Corp Acquires 337,008 Shares of Thermo Fisher Scientific Inc. $TMO

Van ECK Associates Corp grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 77.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 770,774 shares of the medical research company’s stock after buying an additional 337,008 shares during the quarter. Van ECK Associates Corp owned 0.21% of Thermo Fisher Scientific worth $373,841,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FourThought Financial Partners LLC lifted its position in shares of Thermo Fisher Scientific by 0.6% during the third quarter. FourThought Financial Partners LLC now owns 10,212 shares of the medical research company’s stock worth $4,953,000 after purchasing an additional 58 shares during the last quarter. Tiemann Investment Advisors LLC lifted its holdings in Thermo Fisher Scientific by 8.5% during the third quarter. Tiemann Investment Advisors LLC now owns 563 shares of the medical research company’s stock worth $273,000 after buying an additional 44 shares during the period. Winthrop Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 1.2% during the 3rd quarter. Winthrop Capital Management LLC now owns 1,821 shares of the medical research company’s stock valued at $883,000 after buying an additional 22 shares during the last quarter. Dixon Mitchell Investment Counsel Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.7% in the 3rd quarter. Dixon Mitchell Investment Counsel Inc. now owns 211,097 shares of the medical research company’s stock valued at $102,507,000 after purchasing an additional 1,385 shares during the period. Finally, Capital World Investors raised its holdings in Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on TMO shares. UBS Group reiterated a “neutral” rating and set a $615.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Barclays upped their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Citigroup raised their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Robert W. Baird set a $653.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $633.68.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Up 1.7%

NYSE:TMO opened at $510.28 on Tuesday. The stock has a fifty day moving average price of $565.80 and a two-hundred day moving average price of $549.24. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The stock has a market capitalization of $189.56 billion, a price-to-earnings ratio of 28.76, a PEG ratio of 2.89 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period last year, the firm posted $6.10 EPS. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be given a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Friday, March 13th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.70%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.